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A B S T R A C TObjectives: Cystic fibrosis (CF) is an inherited disease that requires
more intensive treatments as the disease progresses. Recent medical
advancements have improved survival but have also increased costs.
Our lack of understanding on the relationship between disease
severity and lifetime health care costs is a major impediment to the
timely economic assessment of new treatments. Methods: Using data
from three waves of the Australian Cystic Fibrosis Australia Data
Registry, we estimate the annual costs of CF care by age and health
state. We define health states on the basis of annual lung-function
scores and patient’s organ transplant status. We exploit the long-
itudinal nature of the data to model disease progression, and we use
this to estimate lifetime health care costs. Results: The mean annual
health care cost for treating CF is US $15,571. Costs for patients with
mild, moderate, and severe disease are US $10,151, US $25,647, and USsee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.12.003
gool@chere.uts.edu.au.
ondence to: Kees van Gool, Centre for Health Econo
ay, NSW 2007, Sydney, Australia.$33,691, respectively. Lifetime health care costs are approximately US
$306,332 (3.5% discount rate). The majority of costs are accounted for
by hospital inpatients (58%), followed by pharmaceuticals (29%),
medical services (10%), complications (2%), and diagnostic tests (1%).
Conclusions: Our study is the first of its kind using the Australian
Cystic Fibrosis Data Registry, and demonstrates the utility of long-
itudinal registry data for the purpose of economic analysis. Our
results can be used as an input to future economic evaluations by
providing analysts with a better understanding of the long-term cost
impact when new treatments are developed.
Keywords: Australia, cost of illness, cystic fibrosis, registry data.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Cystic fibrosis (CF) is the most common life-shortening genetic
disease, with an incidence of 1 in 2500 and carrier frequency of 1
in 25, among Caucasians [1]. With recent advances in treatment,
most children with CF now can expect to survive into adulthood
and life expectancy has improved considerably. CF is a progres-
sive disease that affects many organ systems. As the disease
progresses, patients require more intensive health care that
includes home-based care, medications, more frequent and
prolonged hospital admissions, and, in around half of all cases,
lung transplantation [2,3]. With the advent of new and improved
treatment options, the patterns of care have changed and this
has had an impact on both health care costs and patient out-
comes. For example, two of the key medications developed in the
last 15 years, dornase alfa (Pulmozyme) and tobramycin (Tobi),
cost around US $10,000 per annum and more sophisticated
technology, such as gene-based treatments, may be even more
expensive. Ever increasing pressures on health care budgets
mean that health care decision makers are expected to require
evidence on the cost-effectiveness of new treatments before
funding is approved.
Cost-effectiveness analysis requires a sound understanding of
the long-term costs of care for CF. In particular, information onhow treatment costs are altered when disease progression is
slowed would be a valuable input to future economic analysis.
The aim of this study was to provide researchers with estimates
of the long-term costs and consequences of CF progression. Such
estimates will be of particular value to policymakers and evalua-
tors who wish to examine the potential cost impact of new
technologies. The results reported in this study will allow short-
term clinical trial results to be extrapolated over the longer term.
Previous Literature
There have been a small number of studies that examined the
cost of care associated with CF. A systematic review identified
eight cost-of-illness studies, but only five of these were based on
individual patient care data, with the other three based on cost
estimates provided by clinical experts [4]. We have identified four
further studies that were published after the Krauth et al. [4]
review. Table 1 summarizes each of the studies that were based
on patient data. The average annual health care cost ranged from
US $8,148 to US $50,723 (in constant 2009 dollars). Some studies
found considerable cost variation among patients with CF
depending on the patient’s lung function, whereas others found
no significant effect. For example, the study by Lieu et al. [10]
found that the average annual health care cost for a patient withSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 4 5 – 3 5 5346poor lung function was seven times greater than for a person
with relative good lung function status. A more recent study by
DeWitt et al. [14] found that baseline lung function score was not
a significant predictor of health care costs.
These studies have been limited by their data. The small
sample size of all studies (ranging from 65 to 352) limits their
ability to examine differences in the cost among different
population groups. For example, the study by Baumann et al. [8]
relied on children’s resource use data to estimate costs of adult
patients. Other studies were limited by the scope of the data
collection. For example, Horvais et al. [12] included out-of-
hospital costs but did not have data on inpatient treatments
and Heimeshoff et al. [11] focused on patients treated in one
center. Consequently, these studies are limited in their ability to
provide an overall assessment of the lifetime health care costs for
the entire CF population.
Our study is based on the Australian Cystic Fibrosis Data
Registry (ACFDR). The longitudinal nature of this data allows us
to estimate the rate of CF progression, and its large sample size
allows us to calculate the rate of disease progression for various
age groups and health states as well as the health care costs
associated with treating CF. The results from the transition and
cost analysis are then combined to arrive at the estimated
lifetime costs of CF.Methods
Data
Three years of data from the ACFDR were used (2003, 2004, and
2005), with de-identified data from participants that can be linked
across these years. The ACFDR includes information on clinical
measures, mortality, demographics, complications, and health
care resource use. For more information on the ACFDR, including
descriptive analysis and data items, see the reports published by
Cystic Fibrosis Australia [15,16].
Estimating Transitional Probabilities to Model Disease
Progression
The ACFDR contains data on the forced expiratory volume in 1
second as a percentage of predicted volume (FEV1%)—a standard
measure of lung function. Severity of lung disease is the key to
the quality and length of life [17] of patients with CF. The best
recorded FEV1% measure in each year was used to classify health
states. We chose the FEV1% cutoff scores for severity states 1, 2,
and 3 on the basis that these were consistent with a previous US
study that examined the cost of CF care [10]. We generated a
separate category for patients who had received a lung transplant
because these patients require medications and health care
services that are in addition to standard CF care [18]. For this
reason, transplant patients were assumed to remain in health
state 4 unless a death was recorded. Death is the fifth and
absorbing health state. Patients can therefore progress through
five health states, defined as follows: Health state 1—mild disease where FEV1% Z70
 Health state 2—moderate disease where 40 r FEV1%o 70
 Health state 3—severe disease where FEV1%o 40
 Health state 4—where a patient has received a heart and/or
lung transplant
 Health state 5—where a patient has died.
Patients in the CF registry with FEV1% observations in at least
two separate years were included in estimating the transition
probabilities. Those with fewer than two health state
HS 1:
Mild 
disease
HS 5:
Death
HS 4:
Transplant
HS 3:
Severe
disease
HS 2:
Moderate 
disease
HS 1:
Mild 
disease
HS 4:
Transplant
HS 5:
Death
Fig. 1 – Disease progression model. (A) Age 0 to 7 years. (B) Age 8 years and older. HS, health state.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 4 5 – 3 5 5 347observations were excluded in calculating transition probabilities
(n ¼ 877). Generally, lung function tests cannot be performed by
children younger than 8 years. We therefore combined health
states 1, 2, and 3 for this age group.
By using data from the ACFDR, we employed a Markov
approach to estimate the annual probability of disease progres-
sion for patients with CF. Figure 1 illustrates the disease progres-
sion model. Figure 1A shows the model for children younger than
8 years, and Figure 1B shows the model for everyone else. A
discrete time transition matrix was calculated for each age group,
allowing transition probabilities to vary as the cohort moves from
one age group to the next. The probabilities were estimated onTable 2 – Australian unit prices and annual costs for CF-
to nearest dollar.
CF registry data item Name
Oral/inhaled antibiotics (as
required)
Amoxycillin with clavulanic a
Oral/inhaled antibiotics
(continuous)
Amoxycillin with clavulanic a
Pulmozyme Dornase alfa (Pulmozyme)a
Pancreatic enzyme (age r10 y) Creon 5000a
Pancreatic enzyme (age410 y) Creon Fortea
Vitamins (age r12 y) VitABDECKb
Vitamins (age4 12 y) VitABDECKb
Oral corticosteroid (age r10 y) Panafcortelone solone (5 mg
Oral corticosteroid (age410 y) Panafcortelone solone (25 mg
Inhaled corticosteroid Budesonide (powder)a
Macrolides (age r 10 y) Zithromax 500 mga
Macrolides (age410 y) Zithromax 500 mg
Bronchodilators Salbutamol sulfate (Ventolin
Terbutaline sulfate (Bricanyl
Average
Salt (age r 12 y) Toppin salt tabletsc
Salt (age4 12 y) Toppin salt tabletsc
Antihypercalcemics Bisphosphonates—Risedronate sod
mga
Gastric acid reduction Omeprazol (Acimax)a
Nutritional supplement Energy drinkd
Sources. a ¼ DOHA [20]; b ¼ Cystic Fibrosis NSW [24]; c ¼ online pharm
CF, cystic fibrosis.the basis of the number of patients in a given health state in the
second observation, conditional on their health state in the first
observation. We used a constant annual cycle length to model
disease progression and used the life table solution to compen-
sate for the underestimation of state membership that occurs in
a discrete Markov process [19].
Each patient observation was assigned to 1 of 14 age groups.
Each age group represents 3 years, with the exception of the last
age group, which represents all those aged 38 years and older, and
the third age group, representing children aged 6 and 7 years. We
chose the maximum number of age groups while ensuring that
each group contained at least 30 patients and that each age grouprelated medicines (converted to US $ 2009) – rounded
Units per
year
Unit price
($)
Unit cost per annum
($)
cida 8 13 105
cida 52 13 668
12 814 9770
11 84 918
27 97 2660
6 16 96
12 16 191
)a 6 6 32
)a 12 7 83
12 23 276
39 18 707
78 18 1415
)a 12 9 106
)a 12 16 188
0 147
4 8 30
8 8 61
ium 35 13 37 481
12 29 348
365 1 493
acy; d ¼ Government of Western Australia [25].
Table 3 – Australian unit prices for CF-related
medical services, procedures, and hospitalizations
(converted to 2009 US $).
CF registry data
item
Description Unit
cost
($)
Clinical visit (first
annual visit)a
A clinical visit comprises
an initial specialist
consultation and three
allied health services
(i.e., dietetics,
occupational therapy,
and physiotherapy). The
unit cost is based on
relevant MBS Fees items
(MBS items 132, 10954,
10958, and 10960)
286
Clinical visit
(subsequent visit)a
A clinical visit comprises a
subsequent specialist
consultation and three
allied health services
(i.e., dietetics,
occupational therapy,
and physiotherapy).
Assumes that
subsequent visits take
less specialists’ time.
The unit cost is based
on relevant MBS Fees
items (MBS items 133,
10954, 10958, and 10960)
204
Lung function testa Respiratory Function Tests
(MBS item 11503)
86
Sweat chloride testa Performance of sweat
collection by
iontophoresis for
chloride analysis
35
Genotypingb CFTR mutation detection
for 12 mutations
152
General pathology tests
and pancreatic
insufficiency testsa
The average unit cost per
pathology test is
composed of a
microbiology sputum
culture, full blood cell
count and liver function
tests, vitamin (A, D, and
E) level measurement,
oral glucose tolerance
test, fecel fat (MBS
items 69318, 66674,
66677, 65070, and 66500)
43
Endoscopya This service is composed
of a specialist and
anesthetist
consultation,
bronchoscopy for
children or an
endoscopy for adults
(MBS items 104, 17610,
20520 and 41889 or
30473)
277
Home IVc Based on the average
treatment cost for home
IV therapy based on a
6,794
Table 3 – continued
CF registry data
item
Description Unit
cost
($)
randomized controlled
study in Queensland (n
¼ 82)
Oxygen therapyd Continuous therapy or
nocturnal therapy
2,372
Oxygen therapy
(temporary)d
Temporary—based on 6-
mo usage per year
1,185
CF-related hospital
staye
Average inpatient cost per
day (based on AR-DRG
E60A and E60B)
932
Transplant surgerye Cost of lung/heart
transplant surgery. The
cost has been
annualized by dividing
surgery cost by the
expected number of life
years remaining
69,756
Sources. a ¼ [23]; b ¼ Genetic Health Services Victoria—personal
communication; c ¼ [25]; d ¼ [24]; e¼ [21].
CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conduc-
tance regulator; IV, intravenous; MBS, Medicare Benefits Schedule.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 4 5 – 3 5 5348represented a similar number of years. The annual transition
probabilities vary between age groups but not within an age group.
For the purpose of modeling CF transitions, the disease was
assumed to be progressive, meaning that patients could not
improve their health state. The data showed that out of 2255
patients, 83 patients contradicted this assumption and improved
their FEV1% score and thereby also improved their health state.
After we allowed a margin of error of 10% in the cutoff scores for
health states 1, 2, and 3, only nine patients still improved their
health state. For the purposes of ensuring a progressive disease
model, we deleted these nine records from the transition prob-
ability calculations.Resource Use and Unit Costs Data
The ACFDR contains resource use data on the number of CF-
related hospitalizations in a year, the prescription medications
administered, types of dietary supplements used, number of
clinical visits, use of oxygen therapy, and some pathology tests.
In addition, data exist on whether a patient has undergone a lung
transplant and on death status. Resource use for medicines and
pathology tests is reported as a binary value in the ACFDR,
indicating whether a particular patient is consuming a type of
medication or has undertaken a test that year. The clinical
authors (J.M. and M.D.) supplemented the ACFDR data by provid-
ing the drug names typically used in the management of CF as
well as information on the typical number of scripts required per
year. In some instances, the type of drug and the number of
scripts depend on the age of the patients. These variations have
been incorporated into the analysis.
Unit cost information was obtained from standard Australian
sources that are routinely used in economic evaluations: the
National Hospital Cost Data Collection, the Pharmaceutical Ben-
efits Schedule for all prescription drug costs, and the Medicare
Benefits Schedule for medical consultations and diagnostic test
costs [20–23]. Where necessary, these were supplemented by cost
information from the literature [24–27].
Table 4 – Baseline characteristics for transition
probabilities sample.
Variable Sample SD
Patients 2255
Proportion male 0.52 0.50
Mean FEV1% PP
(aged 8 y and older only) 78.58 23.69
Mean age (y) 15.43 11.52
Age profile, proportion (y):
Aged 0–8 0.32 0.47
Aged 9–16 0.28 0.45
Aged 17–25 0.20 0.40
Aged 26–37 0.14 0.35
Aged older than 37 0.06 0.23
HS, proportion
HS 1: mild disease 0.75 0.43
HS 2: moderate disease 0.16 0.36
HS 3: severe disease 0.05 0.22
HS 4: transplant patient 0.04 0.19
HS, health state.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 4 5 – 3 5 5 349Table 2 lists the unit prices for each CF-related medicine
identified in the ACFDR. In most instances, CF-related medicines
are listed on the Pharmaceutical Benefits Schedule, which enti-
tles patients to a government subsidy, although they may still
face co-payments. Unit prices include the cost to government
and patient. Some CF-related medicines such as vitamins are not
listed on the Pharmaceutical Benefits Schedule, and patients
have to pay the full amount out of their own pocket.
Table 3 lists the unit prices for each of the CF-related
medical services, procedures, and hospitalizations that are
identified in the ACFDR. In most instances, CF-related services
are subsidized by Australia’s universal Medicare program.
Based on clinical advice, a clinical visit comprises consulta-
tions with a specialist medical practitioner and three allied
health care workers, which may include nutritionists, phy-
siotherapists, and social workers and nurses.
Cost Analysis
For each patient, a total annual health care cost was estimated
on the basis of the individual patient’s resource use for that
year. For each age group, health care costs were aggregated for
four out of five health states. No costs could be incurred after
death. The immediate costs associated with transplants were
based on the Australian National Hospital Cost Data Collection
[21]. To obtain an annualized cost, the cost of transplant surgery
was divided by the difference between the patient’s age at
surgery and the maximum age in the data set (47 years). Thus,
the average annual surgery cost increases as the age of the
patient at the time of the transplant increases. Ongoing health
care costs for transplant patients, incurred postsurgery, were
estimated by using data from the ACFDR.
The lifetime costs were estimated on the basis of the sum of
the expected costs for each year of life, as set out in Equation 1:
Lifetime_costs¼
X47
a¼0
X4
s¼1 PasCas ð1Þ
where P is the probability of a patient with CF at age a, and in
health state s, and C is the discounted annual health care costs of
managing a patient with CF. The main lifetime cost results are
based on a life expectancy of 47 years. We chose this cutoff point
because this was the age of the oldest patient in the data set. As a
test of sensitivity, however, we also report the lifetime cost up to
age 65 years. Future health care costs were discounted at 0%,
3.5%, and 5%.
Because of the skewness of cost data, we report both mean
and median costs for each health state and age group. In addition,
we estimated a 95% confidence interval of mean costs by using a
bootstrap method. The confidence intervals were estimated on
the basis of 2000 replications for each age group and health state.
The lower and upper bounds of the interval were used in the
sensitivity analysis for the lifetime cost analyses.
The perspective taken in this analysis is that of the health
care system. While this approach ignores important patient and
family costs associated with the disease (such as lost produc-
tivity by parents and patients as well as travel costs associated
with receiving care), it is consistent with most economic
evaluations in health care and is certainly advocated by Aus-
tralian guidelines on health economic evaluation and elsewhere
[28]. Wherever possible, we have attempted to use the overall
health system costs including contributions made by third-
party payers (usually government) as well as out-of-pocket
costs incurred by patients for prescription drugs. All costs
reported use 2009 price levels and, where necessary, prices
have been adjusted by using the Australian Bureau of Statistics’
Consumer Price Index [29]. All currencies have been converted
to US dollars by applying OECD GDP purchasing power parities
(PPP) conversion rates and using the Campbell and CochraneEconomics Methods Group (CCEMG) – Evidence for Policy and
Practice Information and Co-ordination (EPPI)-Centre Cost Con-
verter (see http://eppi.ioe.ac.uk/costconversion/default.aspx for
more details). The PPP conversion rate used in this study was US
$1 is equal to AU $1.45.Results
Transitional Probabilities
The three waves of ACFDR data provided 4032 transition records
from 2255 individual patients. Patients with FEV1% data in all
three waves (n ¼ 1623 patients) provided two transition records
(i.e., the probabilities of transition from first-year data to the
second-year data and from the second to the third year). For
patients with an FEV1% observation in the first and third years
(2003 and 2005), we linearly extrapolated the FEV1% lung-
function score for the second year and then allocated a health
state accordingly (n ¼ 154). These patients also provided two
transition records. A further 478 patients provided FEV1%
observation in two subsequent ACFDR years. These observa-
tions were used to calculate one transition record. Those
patients who died during the observation period but had no
prior FEV1% values recorded were assumed to have suffered
from severe disease prior to death (health state 3). Table 4
shows the baseline patient characteristics for the 2255 patients
in the sample used to calculate transitions. The mean age was
15 years, and slightly more than half the sample was male. The
average FEV1% score for those aged 8 years and older was 78.6,
indicating that the mean health state is mild disease. Around
one third of the sample was aged 8 years or younger, and only
6% of the patients were older than 37 years.
The transitional probabilities for disease progression for each of
our five health states are reported in Table 5, with each row
representing a different age group. The numbers in the table
represent the annual likelihood of remaining in the same health
state or moving to another state, conditional on last year’s health
state. For example, between the ages of 8 and 10 years, there
Table 5 – Annual CF disease progression transition probability matrix by age group (standard error).
Age group
(y)
From HS 1 to HS 1 to 5 From HS 2 to HS 2 to 5 From HS 3 to HS 3 to 5 From HS 4 to
HS 4 or 5
Absorbing
state
191 291 391 491 591 292 392 492 592 393 493 593 494 594 595
0–2 1 0 0 1 0 1
– – – – – –
3–5 1 0 0 1 0 1
– – – – – –
6–7 0.997 0.000 0.003 1 0 1
(0.001) – – – (0.001) – – – – – – – – – –
8–10 0.973 0.027 0.000 0.000 0.000 1 0 0 0 1 0 0 1 0 1
(0.004) (0.004) – – – – – – – – – – – – –
11–13 0.966 0.031 0.000 0.003 0.000 0.935 0.065 0 0 0.5 0 0.5 1 0 1
(0.004) (0.004) – (0.001) – (0.016) (0.016) – – (0.224) – (0.224) – – –
14–16 0.952 0.045 0.000 0.003 0.000 0.9 0.075 0 0.025 0.5 0.167 0.333 0.833 0.167 1
(0.005) (0.005) – (0.001) – (0.021) (0.019) – (0.011) (0.100) (0.075) (0.094) (0.075) (0.075) –
17–19 0.885 0.109 0.000 0.000 0.005 0.947 0.053 0 0 0.8 0.2 0 1 0 1
(0.011) (0.010) – – (0.002) (0.013) (0.013) – – (0.060) (0.060) – – – –
20–22 0.879 0.121 0.000 0.000 0.000 0.92 0.08 0 0 0.806 0.032 0.161 1 0 1
(0.011) (0.011) – – – (0.013) (0.013) – – (0.032) (0.014) (0.030) – – –
23–25 0.904 0.096 0.000 0.000 0.000 0.897 0.09 0 0.013 0.769 0 0.231 0.909 0.091 1
(0.013) (0.013) – – – (0.015) (0.015) – (0.006) (0.054) – (0.054) (0.028) (0.028) –
26–28 0.917 0.083 0.000 0.000 0.000 0.902 0.082 0.016 0 0.765 0 0.235 0.95 0.05 1
(0.015) (0.015) – – – (0.017) (0.016) (0.007) – (0.047) – (0.047) (0.022) (0.022) –
29–31 0.857 0.143 0.000 0.000 0.000 0.986 0 0 0.014 0.75 0.05 0.2 1 0 1
(0.023) (0.023) – – – (0.006) – – (0.006) (0.044) (0.022) (0.041) – – –
32–34 0.839 0.161 0.000 0.000 0.000 0.911 0.054 0.018 0.018 0.667 0.167 0.167 0.933 0.067 1
(0.030) (0.030) – – – (0.017) (0.014) (0.008) (0.008) (0.064) (0.050) (0.050) (0.030) (0.030) –
35–37 0.788 0.212 0.000 0.000 0.000 0.9 0.1 0 0 0.783 0 0.217 0.944 0.056 1
(0.032) (0.032) – – – (0.021) (0.021) – – (0.039) – (0.039) (0.025) (0.025) –
437 0.884 0.116 0.000 0.000 0.000 0.914 0.057 0.014 0.014 0.844 0.044 0.111 0.94 0.06 1
(0.022) (0.022) – – – (0.015) (0.012) (0.006) (0.006) (0.024) (0.014) (0.021) (0.015) (0.015) –
Note. Lung function cannot be identified in the data for children aged younger than 8 y and therefore health states 1, 2, and 3 were aggregated for this group of patients. Absolute patient
numbers are available on request to the corresponding author. CF, cystic fibrosis.
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Fig. 2 – Proportion of patients in each health state (HS) by age.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 4 5 – 3 5 5 351is an annual 2.7% chance that a patient will move from health state
1 to 2.
Figure 2 illustrates how, over time, the cohort progress from
one health state to another. At age 45 years, the model predicts
that approximately two-thirds of the cohort have died, approxi-
mately 10% have received a transplant, and 1%, 15%, and 8% are
in health states 1, 2, and 3, respectively.Table 6 – Proportion of patients using medicines and me
1
Gastric acid reduction 0.046
Oral antibiotics (as required) 0.496
Oral antibiotics (continuous) 0.247
Inhaled antibiotics (as required) 0.264
Inhaled antibiotics (continuous) 0.103
Macrolides 0.062
Nutritional supplements 0.121
Salt tablets 0.209
Antihypercalcemics 0.002
Vitamin supplementation 0.562
Oxygen therapy (continuous) 0.000
Oxygen therapy (nocturnal) 0.001
Oxygen therapy (as required) 0.000
Endoscopy 0.022
Home IV therapy 0.088
Dornase alfa (Pulmozyme) 0.157
Pancreatic enzymes 0.678
Bronchodilators 0.372
Corticosteroids (inhaled) 0.236
Corticosteroids (oral) 0.070
Therapeutic bronchial artery embolization 0.001
Sweat chloride test 0.015
CFTR mutation analysis 0.021
CFTR, cystic fibrosis transmembrane conductance regulator; IV, intravenResource Use
To estimate cost and resource use, we include all observations in
the registry with an identifiable health state. The sample for this
part of the analysis consisted of 3149 patients providing 5938
observation records. This is larger than the transition probabil-
ities sample size because patients had to provide only one healthdical services.
Health state
2 3 4
0.100 0.176 0.204
0.488 0.545 0.333
0.306 0.325 0.401
0.387 0.388 0.185
0.269 0.339 0.148
0.254 0.380 0.247
0.270 0.449 0.173
0.218 0.218 0.105
0.010 0.028 0.037
0.662 0.699 0.537
0.002 0.050 0.056
0.011 0.079 0.043
0.003 0.006 0.043
0.037 0.061 0.105
0.256 0.337 0.266
0.418 0.485 0.241
0.747 0.766 0.642
0.601 0.672 0.327
0.398 0.391 0.296
0.107 0.083 0.457
0.013 0.017 0.012
0.001 0.000 0.000
0.006 0.008 0.000
ous.
Table 7 – Number of services used per annum by
patients with CF.
Health state
1 2 3 4
Pathology tests 2.7 4.7 6.0 4.6
Lung function test 1.7 3.7 3.1 1.8
Clinical visits 4.6 5.9 6.1 5.0
Hospital days 6.1 17.4 24.5 17.5
Hospital separations 0.9 1.7 2.2 1.7
CF, cystic fibrosis.
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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 4 5 – 3 5 5352state record (instead of at least two) to be included in the cost
analysis.
Table 6 provides a summary of the proportion of patients who
are consuming medicines identified in the CF registry data as well
as tests and medical services. The use of some medicines such as
antibiotics appears to be stable across health states, but the use
of most treatments rises as the disease progresses. Tests such as
cystic fibrosis transmembrane conductance regulator analysis
and sweat chloride tests are undertaken more often when
patients are in the early severity stages of CF. This is an
indication that such tests are used for the initial CF diagnosis.
Table 7 summarizes the annual number of medical services used
by patients with CF according to their severity. On average, patients
in health state 1 were admitted to hospital for 6.1 days for CF-related
purposes. This number rises to 24.9 days for those in health state 3
and falls to 17.5 days for those who have undergone transplant
surgery, although it should be noted that this does not include the
days spent in the hospital for the actual transplant surgery.
Annual Costs
Table 8 shows the annual health care costs associated with the
management of CF and associated complications for each age
group and health state. The mean, bootstrapped standard error,
and median are presented. Overall, the mean annual cost asso-
ciated with CF management is US $15,571, with a 95% confidence
interval range of US $15,032 to US $16,110. For health states
combined, annual health care costs decline somewhat after age
2 years, then generally rise until patients reach their early thirties,
then plateau at around US $20,000 to US $25,000 per year. Based on
the standard errors reported in Table 8, the decrease in health care
after age 2 years is statistically significant, as are the increases in
the teenage years. The overall median health care cost is US $6,233
per year and ranges from US $2,269 for children aged 6 to 7 years
to US $16,704 for 26- to 28-year-old patients. The difference
between the mean and median statistics indicates that health
care costs are highly skewed. This is not unusual in health care
cost data where a small number of patients are very high users of
health care resources and thereby greatly influence mean costs.
Both mean and median costs rise significantly as the disease
progresses from health state 1 to 3. For all ages combined, when
patients progress from health state 1 to 2, both mean and median
health care costs increase by around US $15,000. While the
average annual cost for health state 4 (patients who have
received a transplant) is higher than that for health state 3, the
difference is not statistically significant. The median cost for
health state 4 is slightly lower than that for health state 3.
Cost by Health Care Sector
Figure 3 illustrates the distribution of total costs by main health
care sector for each health state. The figure demonstrates that
1% 2% 3% 3%
34% 28% 24%
13%
13%
9%
9%
6%
50%
59% 64%
77%
2% 2% 1% 1%
0%
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40%
50%
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70%
80%
90%
100%
1 2 3 4
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Tests
Hospitalizations
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Pharmaceuticals
Complications
Fig. 3 – Distribution of CF health care costs by health state. CF, cystic fibrosis.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 4 5 – 3 5 5 353the greatest proportion of costs in the management of CF is
incurred in the hospital sector, ranging from 50% for patients
with mild disease (health state 1) to 77% for patients who have
undergone a transplant operation (health state 4). The next
biggest sector is pharmaceuticals, ranging from 13% in patients
with severe disease (health state 3) to 33% for patients with mild
disease (health state 1). This provides some indication that, in
relative terms, care shifts from pharmaceutical management to
hospital management as CF progresses.
Lifetime Costs and Total Health System Cost
Table 9 presents the results on lifetime health care costs up to age
47 years. Two estimates based on mean and median annual costs
are produced. As a large proportion of health care costs is
incurred in future years, it is appropriate that a discount rate is
applied. Table 9 presents results where future health care costs
are discounted at 0%, 3.5%, and 5% per year after the first year.
Using a 3.5% discount rate, mean and median lifetime health care
costs are estimated to be around US $306k and US $190k,
respectively. If we were to run the model up to age 65 years,
the mean (median) lifetime health care costs are estimated to be
$320k ($200k) applying a 3.5% discount rate. On the basis that
there are around 3000 patients with CF in Australia, the annual
health system costs is in the vicinity of US $47 million.Conclusions
We have successfully developed a model of CF disease progres-
sion to estimate the cost of medical care for people with CF. The
mean annual cost for managing patients with CF is US $15,571,Table 9 – Total lifetime costs—mean, median, and 95% co
Discount rate (%) Mean
L
0 637,943 52
3.5 306,332 25
5 235,666 19with a lifetime cost of US $306k. The health care costs rise as a
patient’s disease progresses. Average costs for patients with
severe disease were three times higher than those for patients
with mild disease. This indicates that potential new therapies
that can delay disease progression may have important cost-
offsets that need to be incorporated in economic evaluations.
There are several limitations in this study. First, the scope
of ACFDR is not complete. Patients with CF who do not attend
one of the participating treatment centers will not be captured
by the data. Although a recent report by Cystic Fibrosis
Australia estimates that its registry now captures around 90%
of all patients [30], the percentage was lower in the data
available for this study. Second, coverage of the CF registry in
terms of resource use is also not complete. As a result, some
health care costs such as general practitioner attendances are
not included in the analysis. Similarly, CF registry data may
not be comprehensive in capturing resource use associated
with CF-related complications such as diabetes and liver
disease. We have tried to overcome such gaps by using cost
evidence from other studies, but these tend to be estimated on
a population basis. It may well be the case that this is an
underestimate of the true costs. This is because the cost of
treating complications among patients with CF may be higher
than the cost of treating similar complications in those who do
not have CF and are otherwise healthy. These issues could be
addressed by linking ACFDR with administrative data sets that
provide detailed information on health care use and costs. The
ACFDR would be further enhanced by seeking quality-of-life
information from patients and carers. The addition of quality-
of-life data and improved resource use data would make the
ACFDR a powerful tool for future analysis, and a truly uniquenfidence interval (converted US $)—by discount rate.
95% confidence interval Median
ow High
0,142 781,487 419,734
6,098 375,304 189,825
8,942 288,800 141,955
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 4 5 – 3 5 5354asset in Australia. This data set can be used to undertake
important economic and outcomes research. Third, the ana-
lysis uses only 3 years of registry data, limiting our ability to
examine disease progression over a longer period of time.
Cystic Fibrosis Australia is currently undertaking work to
enable more linkage across waves. When this work is com-
plete, it will allow researchers to utilize the panel structure of
the data more fully.
Finally, there was a large number of missing FEV1% values in
the ACFDR. These are most likely due to issues of data collection,
rather than patient selection. Despite these high numbers, our
sample captures around 80% of the CF population. As children
cannot generally perform the required lung function test, FEV1%
values are also missing for those younger than 8 years. As a
result, we made an assumption about these children’s health
states. An important area for future research will be to model
disease progression among the very young by using alternative
markers of severity [31].
Notwithstanding these limitations, our results appear to be
consistent with earlier research. Our assumption that CF is a
strictly progressive disease (i.e., lung function does not improve)
after taking into account patients who had undergone transplant
surgery also appears to be validated by the data. Our estimate, in
terms of mean annual costs, is less than those found in some
studies but greater than the mean costs found in the 1996
Canadian study by Johnson et al. [6,12,13,32]. Care should be
taken in comparing these results because there are differences in
methodologies and patient groups. For example, Eidt-Koch et al.
[13] focused only on outpatient medication costs and the patient
group studied in Heimeshoff et al. [11] was older and suffered
more severe disease compared with the group in the present
study. The results of the current study are similar to those
reported by Robson et al. [5], Ireys et al. [7], and Lieu et al. [10].
In the case of Lieu et al. [10], the median costs are also similar to
those in the present study.
This study makes a number of important contributions to
the existing literature. It is the first analysis to develop a model
of disease progression and thereby estimate lifetime costs, by
using longitudinal registry data. Second, this study has used a
much larger sample size than previous studies, enabling us to
estimate costs on the basis of age and severity. Third, we have
incorporated transplantation costs into the analysis and exam-
ined the impact of such surgery separately to other categories of
severity. Fourth, reporting resource use and standard costs facil-
itates more transparent translating of study results to other
jurisdictions.
The value of our approach in estimating health care costs
alongside disease progression is that it will enable future
researchers to estimate the long-term impact of new treatments
and health services. The model can extrapolate the short-term
results of new treatments on outcomes and cost over the longer
term. This will enable more timely evaluation of new treatments,
with consistent and reliable evidence that reduces the degree of
uncertainty in funding decisions. This will become even more
important with the promise of new therapies in the R&D pipeline
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